Navigation Links
Galil Medical Announces Establishment of Global Headquarters in Minneapolis, MN
Date:9/30/2009

MINNEAPOLIS, Sept. 30 /PRNewswire/ -- Galil Medical, a global leader in minimally invasive cryotherapy treatments for cancers and other disorders, announced today that it is establishing its new Global Headquarters in Minneapolis, MN. The company is expected to open this new facility in Arden Hills during the fourth quarter of 2009. Along with its corporate staff and US operations' functions, the company will also locate its global marketing, clinical/regulatory and its systems development and assembly functions in this new facility. Galil Medical will maintain needle manufacturing and R&D operations in its facility in Yokneam, Israel, as well as its European headquarters in London.

Martin J. Emerson, President and CEO, of Galil Medical comments: "We are excited about locating our Global Headquarters in Minneapolis. We feel the strong medical device presence in the greater Minneapolis and St. Paul area will give us access to a wide range of important resources and talent."

James E. Thomas, General Partner of Thomas, McNerney & Partners and member of Galil's Board of Directors, commented: "The decision to locate Galil's Global Headquarters in the Minneapolis area is part of our five year strategic plan recently approved by the Board of Directors. This plan includes the necessary funding for clinical data that will further document the value of cryotherapy for the focal treatment of prostate cancer and the treatment of renal cancer. Importantly, the plan also includes funding for advancing the state of the art cryotherapy technology."

Emerson concluded, "Galil Medical is now the only company solely devoted to the growth and development of cryotherapy. We have the experience, resources and commitment to pursue these goals for years to come."

About Galil Medical Galil Medical is a global medical device company that develops, manufactures and markets innovative products utilizing a proprietary cryoablation platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. The company has offices in Yokneam, Israel; Plymouth Meeting, Pennsylvania; and London. Shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. (Nasdaq: ELRN) and RDC Rafael Development Corporation, Ltd.

SOURCE Galil Medical


'/>"/>
SOURCE Galil Medical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Medical Device Provider Chooses TrackWise(R) Software to Optimize Customer Complaint Handling
2. ReBuilder Medical Technologies, Inc. Reports LOI With National DME Distributor
3. New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal
4. American University of Beirut Medical Team Successfully Performs First Artificial Heart Implant in Lebanon
5. ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis
6. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
7. Medical World Recognises New Therapy for Reflux Babies
8. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
9. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
10. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
11. Medigus and Tower Semiconductor Announce Worlds Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):